Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia

British Journal of Haematology

Volumn 93, Issue 4, 1996, Pages 817-821

  Arya, Roopen ^a,c   Rolan, Paul E ^b   Wootton, Raymond ^b   Posner, John ^b   Bellingham, Alastair J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti sickling agent; Oxygen affinity; Sickle cell anaemia; Substituted benzaldehyde; Tucaresol

Indexed keywords

PLACEBO; TUCARESOL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEVER; HUMAN; LYMPHADENOPATHY; ORAL DRUG ADMINISTRATION; OXYGEN AFFINITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BENZALDEHYDES; BENZOATES; ERYTHROCYTES; HEMOGLOBIN, SICKLE; HEMOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; OXYGEN;

EID: 0029895837     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1744.x     Document Type: Article

References (20)

1. Beddell, C.R., Goodford, P.J., Kneen, G. White, R.D., Wilkinson, S. & Wootton, R. (1984) Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. British Journal of Pharmacology, 82, 397-407.
2. Benesch, R., Benesch, R.E. & Yung, S. (1974) Chemical modifications that inhibit gelation of sickle hemoglobin. Proceedings of the National Academy of Sciences of the United States of America, 71, 1504-1505.
3. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine. 332, 1317-1322.
4. Dean, J. & Schechter, A.N. (1978a) Sickle cell anemia: molecular and cellular bases of therapeutic approaches. Part 1. New England Journal of Medicine, 299, 752-763.
5. Dean, J. & Schechter, A.N. (1978b) Sickle cell anemia: molecular and cellular bases of therapeutic approaches. Part 3. New England Journal of Medicine, 299, 863-870.
6. Franklin, I.M., Rosemeyer, M.A. & Huehns, E.R. (1983) Sickle cell disease: the proportion of liganded haemoglobin needed to prevent crises. British Journal of Haematology, 54, 579-587.
7. Hofrichter, J., Ross, P.D. & Eaton, W.A. (1974) Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 71, 4864-4868.
8. Huisman, T.H.J. (1987) Standard methodology for the detection of haemoglobin abnormalities. The Haemoglobinopathies (ed. by T. H. J. Huisman), pp. 11-13. Churchill Livingstone, Edinburgh.
9. Keidan, A.J., Franklin, I.M., White, R.D., Joy, M., Huehns, E.K. & Stuart, J. (1986) Effect of BW12C on oxygen affinity of haemoglobin in sickle cell disease. Lancet, i. 831-834.
10. Keidan, A.J., Sowter, M.C., Johnson, C.S., Marwah, S.S. & Stuart, J. (1989) Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erethrocytes: a possible therapeutic approach to sickle cell disease. Clinical Science, 76, 357-362.
11. Kenny, M.W. & Stuart, J. (1983) Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation. British Journal of Haematology, 55, 465-471.
12. Kneen, G. & White, R.D. (1981) BW12C: a new anti-sickling agent. British Journal of Pharmacology, 74, 965-970.
13. Merrett, M., Stammers, D.K., White, R.D., Wootton, R. & Kneen, G. (1986) Characterisation of the binding of the antisickling compound 'BW12C' to haemoglobin. Biochemical Journal, 239, 387-390.
14. Perutz, M.F. & Mitchison, J.M. (1950) State of haemoglobin in sickle cell anaemia. Nature, 166, 677-679.
15. Rhodes, J., Chen, H., Hall, S.R., Beesley, J.E., Jenkins, D.C., Collins, P. & Zheng, B. (1995) Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature, 377, 71-75.
16. Rolan, P.E., Mercer, A.J., Wootton, R. & Posner, J. (1995) Pharmacokinetics and pharmacodynamics of tucaresol, an anti-sickling agent, in healthy volunteers. British Journal of Clinical Pharmacology, 59, 375-380.
17. Rolan, P.E., Parker, J.E., Gray, S.J., Weatherley, B.C., Ingram, J., Leavens, W., Wootton, R. & Posner, J. (1995) The pharmacokinetics, tolerability and pharmacodynamics of tucaresol, a potential antisickling agent, following oral administration to healthy subjects. British Journal of Clinical Pharmacology, 35, 419-425.
18. Sher, G.D., Ginder, G.D., Little, J., Yang, S., Dover, G.J. & Olivieri, N.F. (1995) Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. New England Journal of Medicine, 332, 1606-1610.
19. Stamatoyannopoulos, G., Veith, R.W. & Al-Khatti, A. (1987) On the induction of fetal haemoglobin in the adult: stress erythropoiesis, cell-cycle specific drugs, and recombinant erythropoietin. Developmental Control of Globin Gene Expression (ed. by G. Stamatoyannopoulos and A. W. Nienhuis), p. 453. A. R. Liss, New York.
20. Sunshine, H.R., Hofrichter, J. & Eaton, W.A. (1978) Requirements for therapeutic inhibition of sickle haemoglobin gelation. Nature, 275, 238-240.